Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

Inclusion Criteria:

• Patients with predominantly urge incontinence overactive bladder episodes
• Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards

Exclusion Criteria:

• History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia
• Lower urinary tract symptoms associated with benign prostatic hypertrophy
• Active or current Urinary Tract Infections (UTIs)
• Surgery to correct prolapsed uterus or stress incontinence